>미국과 유럽의 연골 재생 시장, 유형별(유리 연골, 섬유 연골 및 탄력 연골), 치료 양식(세포 기반 및 비세포 기반), 치료 유형(내재적 복구 자극 및 완화), 적용 부위(무릎, 고관절, 발목, 척추 및 기타), 수술 절차(골연골 이식, 자가 연골 세포 이식, 기질 자가 연골 이식(MACI), 연골 성형술 및 미세 골절, 골절술, 관절경 검사, 마모성 관절 성형술, 청소년 이식 조각 및 기타), 최종 사용자(병원 및 진료소, 학술 및 연구 기관, 외래 수술 센터, 정형 센터 및 기타) - 산업 동향 및 2031년까지의 예측.
미국 및 유럽 연골 재생 시장 분석 및 규모
골관절염 유병률 증가로 인한 시장 성장을 주도하는 주요 요인 중 하나입니다. 또한, 연구 개발 활동에 대한 투자 증가는 시장 성장을 위한 또 다른 주요 동인입니다. 첨단 의료 인프라를 촉진하는 정부 이니셔티브도 시장에 영향을 미칩니다. 그러나 숙련된 전문가의 부족과 정형외과 임플란트 및 수술과 관련된 높은 비용이 시장 성장을 제한하고 있습니다.
Data Bridge Market Research에 따르면 미국과 유럽의 연골 재생 시장 규모는 2023년 590,964.54달러에서 2031년 1,474,396.99달러로 성장할 것으로 예상되며, 2024년에서 2031년까지의 예측 기간 동안 연평균 성장률은 12.8%일 것으로 예상됩니다.
|
보고서 메트릭 |
세부 |
|
예측 기간 |
2024년부터 2031년까지 |
|
기준 연도 |
2023 |
|
역사적 연도 |
2022 (2016-2021년까지 사용자 정의 가능) |
|
양적 단위 |
수익 (USD 천) |
|
다루는 세그먼트 |
유형(유리 연골, 섬유 연골 및 탄력 연골), 치료 방식(세포 기반 및 비세포 기반), 치료 유형(내재적 복구 자극 및 완화), 적용 부위(무릎, 엉덩이, 발목, 척추 및 기타), 수술 과정(골연골 이식, 자가 연골 세포 이식, 기질 자가 연골 이식(MACI), 연골 성형술 및 미세 골절, 골절술, 관절경 검사, 마모성 관절 성형술, 청소년 이식 조각 및 기타), 최종 사용자(병원 및 진료소, 학술 및 연구 기관, 외래 수술 센터 , 정형 센터 및 기타) |
|
적용 국가 |
미국, 독일, 영국, 프랑스, 이탈리아, 스페인, 러시아, 폴란드, 스위스, 네덜란드, 터키, 스웨덴, 벨기에, 덴마크, 핀란드, 노르웨이 및 기타 유럽 국가 |
|
시장 참여자 포함 |
Zimmer Biomet, Vericel Corporation., Arthrex, Inc., CONMED Corporation., RTI Surgical, Smith+Nephew., Anika Therapeutics, Inc., Geistlich Pharma AG, AlloSource, TETEC AG(B. Braun SE 자회사), meidrix biomedicals GmbH., Bioinova, as, Lamina Therapeutics, CO.DON, Novartis AG, Cartilage Inc., Histogen Inc. 등 |
시장 정의
연골 재생은 인체의 손상되거나 퇴화된 연골 조직을 회복하기 위한 의료 기술과 치료법의 개발 및 적용을 말합니다. 연골은 관절을 지지하고 완충하는 데 중요한 역할을 하는 결합 조직이며, 손상은 부상, 관절염 또는 기타 퇴행성 질환으로 인해 발생할 수 있습니다.
미국과 유럽 연골 재생 시장 동향
이 섹션에서는 시장 동인, 이점, 기회, 제약 및 과제를 이해하는 것을 다룹니다. 이 모든 내용은 아래에서 자세히 설명합니다.
운전자
- 골관절염 유병률 증가
골관절염은 노인에게 더 흔하며, 노령 인구가 증가함에 따라 이 질환의 발병률도 높아집니다. 노화로 인해 관절이 골관절염에 더 취약해집니다. 따라서 노인 인구는 연골 재생 요법에 대한 상당한 시장을 나타냅니다. 비만은 특히 무릎과 엉덩이와 같은 체중을 지탱하는 관절에서 골관절염의 확립된 위험 요소입니다. 전 세계적으로 비만율이 증가함에 따라 특히 젊은 연령대에서 골관절염 발병률이 높아졌습니다. 비만인 개인은 종종 관절에 더 큰 스트레스를 받아 연골 변성이 가속화되고 재생 솔루션에 대한 수요가 발생합니다.
골관절염의 유병률 증가는 연골 재생 시장 성장을 견인하는 강력한 요인입니다. 연골 손상을 해결하기 위한 진보적이고 재생적인 솔루션에 대한 수요는 지역 인구가 고령화되고 골관절염 위험 요소가 지속됨에 따라 계속 증가할 것으로 예상됩니다. 이 시장은 골관절염과 관련된 증가하는 의료 수요를 충족하기 위해 추가적인 발전, 연구 및 혁신을 볼 가능성이 높습니다.
- 연구 개발 활동에 대한 투자 증가
R&D 투자 증가는 재생 의학 에서 첨단 기술의 탐색과 개발을 용이하게 합니다 . 줄기세포 치료, 조직 공학, 3D 바이오 프린팅과 같은 기술은 지속적으로 진화하여 연골 재생을 위한 보다 효과적이고 정확한 솔루션을 제공합니다. R&D 활동은 연골 재생을 위해 특별히 설계된 새로운 제품으로 이어집니다. 제약 회사와 생명공학 회사는 연골 복구의 복잡성을 해결하고 더 나은 환자 결과를 촉진할 수 있는 새로운 약물, 생물학 및 의료 기기를 개발하는 데 투자합니다.
상당한 R&D 투자는 임상 시험 의 시작과 진행을 가능하게 합니다 . 이러한 시험은 새로운 연골 재생 치료법의 안전성과 효능을 평가하는 데 필수적입니다. 긍정적인 시험 결과는 규제 승인과 이러한 치료법의 궁극적인 상용화에 기여합니다. R&D 노력은 연골 퇴화와 재생 메커니즘에 대한 더 깊은 이해에 기여합니다. 이러한 지식은 연골 손상 정도가 다양한 환자의 특정 요구 사항을 해결할 수 있는 표적화되고 개인화된 치료법을 개발하는 데 필수적입니다.
연구 개발 활동에 대한 투자 증가는 혁신을 촉진하고, 치료 방식을 개선하고, 과학적 이해를 증진하고, 궁극적으로 연골 관련 질환이 있는 환자에게 새롭고 효과적인 솔루션을 제공함으로써 시장 성장을 촉진합니다. 이러한 투자는 시장의 진화에 기여하여 재생 의학의 광범위한 분야에서 역동적이고 반응성 있는 부문으로 자리 매김하고 있으며, 이는 시장 성장을 촉진하고 있습니다.
기회
- 최소 침습적 시술에 대한 수요 증가
최소 침습적 시술(또는 최소 침습적 수술)은 필요한 절개 크기를 제한하여 상처 치유 시간, 관련 통증 및 감염 위험을 줄이는 수술 기술을 포함합니다. 수술은 정의상 침습적이며 어느 정도 크기의 절개가 필요한 많은 수술을 개방 수술이라고 합니다. 최소 침습적 수술에는 관절 교체, 스포츠 부상의 관절경 수술 및 복잡한 근골격계 질환의 미세 치료가 포함됩니다. 짧은 회복 시간, 낮은 감염 위험, 적은 출혈, 작은 흉터 및 짧은 입원 기간이 포함됩니다.
MIS에서 사용되는 내비게이션 지원 수술 장비와 같은 기술과 기구는 개방 수술의 경우보다 신체에 덜 손상을 줍니다. 다양한 장애가 있는 환자를 수술하기 위한 최소 침습 기술의 지속적인 발전은 연골 재생 시장의 성장을 촉진할 것으로 예상됩니다.
첨단 기술을 통해 수행되는 최소 침습 수술의 이점은 엄청납니다. 최소 침습 시술에 대한 수요가 증가함에 따라 시장 성장 기회가 창출될 것으로 예상됩니다.
제지/도전
- 연골 재생을 위한 불량한 환불 시나리오
연골 재생 치료에는 종종 비용이 많이 들 수 있는 진보적이고 혁신적인 기술이 필요합니다. 환불이 잘 안 되는 상황에서는 환자가 더 많은 비용을 부담해야 할 수 있으며, 이로 인해 이러한 치료를 감당할 수 있는 능력이 제한될 수 있습니다. 이러한 재정적 장벽은 환자가 연골 재생 시술을 선택하지 못하게 만들어 시장 수요를 감소시킬 수 있습니다. 환불 정책이 비용을 적절히 충당할 때 의사와 의료 서비스 제공자는 연골 재생 치료를 채택하고 권장할 가능성이 더 높습니다. 환불이 잘 안 되는 상황에서는 의료 전문가들이 환자와 그들의 진료에 미치는 재정적 영향에 대해 우려하여 이러한 치료를 제공하는 데 주저할 수 있습니다.
경쟁이 치열한 의료 분야에서는 환불 정책이 시장 역학에 상당한 영향을 미칠 수 있습니다. 연골 재생 치료에 대한 환불이 제한적이거나 일관성이 없다면, 기존 또는 대체 개입과 비교했을 때 이러한 치료법의 경쟁력을 저해할 수 있습니다. 이는 결국 시장의 성장 잠재력을 제한합니다.
연골 재생 기술의 채택은 더 느릴 수 있으며, 강력한 환불 지원 없이는 주류 의료 관행에 통합하는 데 제한이 있을 수 있습니다. 이는 차례로 정형외과적 상태와 부상을 다루는 데 있어서 시장의 확장과 그 잠재력의 완전한 실현을 제한합니다.
최근 개발 사항
- 2023년 5월, 캘리포니아 어바인 대학의 바이오메디컬 스타트업인 Cartilage Inc.는 결손된 조직을 재생하고 턱 관절의 결함을 복구하여 TMJ 기능을 회복하는 제품을 개발하고 있습니다. 이를 통해 회사는 제품 포트폴리오를 강화할 수 있었습니다.
- 2021년 9월, Novartis AG는 미국 식품의약국(FDA)이 LNA043에 대해 무릎 골관절염 치료를 위한 패스트트랙 지정을 부여했다고 발표했습니다. 이를 통해 회사는 골관절염 제품에서 입지를 굳건히 하는 데 도움이 되었습니다.
- 2020년 9월, Lamina Therapeutics는 INSERM UMR 1260/RNM(Regenerative NanoMedicine) 부서장이자 LAMINA THERAPEUTICS 창립 멤버인 Nadia JESSEL 교수가 조정하는 스트라스부르 과학 팀의 연구 작업에 의존한다고 발표했습니다. 이 혁신적인 기술은 특히 뼈, 연골 및 골연골 단위를 재건하기 위한 재생 의학을 위한 차세대 복합 첨단 치료 의약품(cATMP)을 개발하는 것을 목표로 합니다.
- 스포츠 의학 및 중증 화상 치료 시장을 위한 첨단 치료법 분야의 선두주자인 Vericel Corporation은 2021년 1월 United Healthcare가 돼지 콜라겐 막에 배양된 자가 연골세포인 MACI에 대한 의료 정책을 확대하여 슬개골의 증상성 전층 연골 결손 및 무릎의 다중 연골 결손 환자를 포함하도록 했다고 발표했습니다.
- 2020년 10월, Cartilage Inc.는 국립보건원(NIH)으로부터 1단계 252,000달러 규모의 중소기업 혁신 연구(SBIR) 보조금을 받았습니다. 이 스타트업은 이 보조금을 사용하여 스캐폴드가 없는 조직 공학 연골 임플란트인 자사 제품 Hyaleon의 실현 가능성을 조사했습니다.
미국 및 유럽 연골 재생 시장 범위
미국과 유럽의 연골 재생 시장은 유형, 치료 방식, 치료 유형, 적용 부위, 수술 과정, 최종 사용자 등 6가지 주요 세그먼트로 세분화됩니다. 이러한 세그먼트의 성장은 산업의 빈약한 성장 세그먼트를 분석하고 사용자에게 귀중한 시장 개요와 시장 통찰력을 제공하여 핵심 시장 응용 프로그램을 식별하기 위한 전략적 결정을 내리는 데 도움이 됩니다.
유형
- 유리연골
- 섬유 연골
- 탄력 연골
미국과 유럽의 연골 재생 시장은 유형을 기준으로 유리연골, 섬유연골, 탄성연골로 구분됩니다.
치료 방법
- 세포 기반
- 비셀 기반
치료 방식을 기준으로 미국과 유럽의 연골 재생 시장은 세포 기반과 비세포 기반으로 구분됩니다.
치료 유형
- 내재적 수리 자극
- 완화제
미국과 유럽의 연골 재생 시장은 치료 유형을 기준으로 내재적 회복 자극과 완화적 치료로 구분됩니다.
신청 사이트
- 무릎
- 잘 알고 있기
- 발목
- 척추
- 기타
미국과 유럽의 연골 재생 시장은 적용 부위를 기준으로 무릎, 엉덩이, 발목, 척추 및 기타 부위로 구분됩니다.
수술 과정
- 골연골 이식
- 자가 연골세포 이식
- 매트릭스 자가 연골 이식(MACI)
- 연골성형술 및 미세골절술
- 골절술
- 관절경
- 마모성 관절성형술
- 청소년 이식편 조각
- 기타
미국과 유럽의 연골 재생 시장은 수술 방법을 기준으로 골연골 이식, 자가 연골세포 이식, 기질 자가 연골 이식(MACI), 연골 성형술 및 미세 골절, 골절술, 관절경 수술, 마모성 관절 성형술, 청소년 이종이식 조각 및 기타로 구분됩니다.
최종 사용자
- 병원 및 진료소
- 학술 및 연구 기관
- 외래 수술 센터
- 정사중심
- 기타
미국과 유럽의 연골 재생 시장은 최종 사용자를 기준으로 병원 및 진료소, 학술 및 연구 기관, 외래 수술 센터, 정형센터 및 기타로 구분됩니다.
미국 및 유럽 연골 재생 시장 지역 분석/통찰력
미국과 유럽의 연골 재생 시장을 분석하고, 국가, 유형, 치료 방식, 치료 유형, 적용 부위, 수술 절차 및 최종 사용자별로 시장 규모에 대한 통찰력과 추세를 제공합니다.
이 시장 보고서에서 다루는 국가는 미국, 독일, 영국, 프랑스, 이탈리아, 스페인, 러시아, 폴란드, 스위스, 네덜란드, 터키, 스웨덴, 벨기에, 덴마크, 핀란드, 노르웨이, 그리고 기타 유럽 국가입니다.
미국은 다양한 제조업체의 투자 수준이 높고 제약 제품 제조에 대한 수요가 증가함에 따라 미국과 유럽의 연골 재생 시장을 지배할 것으로 예상됩니다. 독일은 연구 개발 활동에 대한 투자가 증가함에 따라 유럽의 연골 재생 시장을 지배할 것으로 예상됩니다.
보고서의 국가 섹션은 또한 현재 및 미래 시장 추세에 영향을 미치는 개별 시장 영향 요인과 시장 규제의 변화를 제공합니다. 하류 및 상류 가치 사슬 분석, 기술 추세, 포터의 5가지 힘 분석, 사례 연구와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 몇 가지 포인터입니다. 또한 지역 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 국내 관세의 영향 및 무역 경로가 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.
미국 및 유럽 연골 재생 시장: 경쟁 환경 및 점유율 분석
미국과 유럽 연골 재생 시장 경쟁 구도는 경쟁자에 대한 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 새로운 시장 이니셔티브, 지역적 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 분야 우세입니다. 제공된 위의 데이터 포인트는 시장과 관련된 회사의 초점에만 관련이 있습니다.
미국과 유럽 연골 재생 시장에서 활동하는 주요 기업으로는 Zimmer Biomet, Vericel Corporation, Arthrex, Inc., CONMED Corporation, RTI Surgical, Smith+Nephew, Anika Therapeutics, Inc., Geistlich Pharma AG 등이 있습니다.
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
목차
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE U.S. & EU CARTILAGE REGENERATION MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 TYPE SEGMENT LIFELINE CURVE
2.8 MARKET END USER COVERAGE GRID
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PSETEL ANALYSIS
4.2 PORTER’S FIVE FORCES
5 NUMBER OF PROCEDURES PERFORMED PER YEAR: BY COUNTRY
6 REGULATIONS
6.1 EUROPE CARTILAGE REGENERATION MARKET: REGULATIONS
6.1.1 CONFORMITY
6.1.2 CLINICAL INVESTIGATION
6.2 U.S. CARTLAGE REPAIRING MARKET: REGULATIONS
6.2.1 FDA CENTER FOR DEVICES AND RADIOLOGICAL HEALTH (CDRH)
6.2.2 FDA CENTER FOR BIOLOGICS EVALUATION AND RESEARCH (CBER)
6.2.3 CLINICAL TRIALS OVERSIGHT
6.2.4 POST-MARKET SURVEILLANCE
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 RISING PREVALENCE OF OSTEOARTHRITIS
7.1.2 RISING INVESTMENTS IN RESEARCH AND DEVELOPMENT ACTIVITIES
7.1.3 RISING HEALTHCARE EXPENDITURE TO PROMOTE CARTILAGE REGENERATION TREATMENT
7.1.4 INCREASING NUMBER OF JOINT INJURIES
7.2 RESTRAINTS
7.2.1 POOR REIMBURSEMENT SCENARIO FOR CARTILAGE REGENERATION
7.2.2 STRINGENT REGULATIONS FOR THE APPROVAL OF CARTILAGE REGENERATION PRODUCTS
7.3 OPPORTUNITIES
7.3.1 INCREASE DEMAND FOR MINIMALLY INVASIVE PROCEDURES
7.3.2 RISING TECHNOLOGICAL ADVANCEMENTS IN THE CARTILAGE REGENERATION PROCESS.
7.3.3 RISING AWARENESS OF MEDICAL TREATMENT IN EUROPE
7.4 CHALLENGES
7.4.1 LACK OF SKILLED PROFESSIONALS IN HEALTHCARE MARKET
7.4.2 HIGH COST OF ORTHOPEDIC IMPLANTS AND SURGERIES
8 U.S. & EUROPE CARTILAGE REGENERATION MARKET, BY TYPE
8.1 OVERVIEW
8.2 HYALINE CARTILAGE
8.3 FIBRO CARTILAGE
8.3.1 INTRA-ARTICULAR FIBROCARTILAGE
8.3.2 STRATIFORM FIBROCARTILAGE
8.3.3 CIRCUMFERENTIAL FIBROCARTILAGE
8.3.4 CONNECTING FIBROCARTILAGE
8.4 ELASTIC CARTILAGE
9 U.S. & EUROPE CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY
9.1 OVERVIEW
9.2 CELL-BASED
9.2.1 CHONDROCYTE TRANSPLANTATION
9.2.1.1 AUTOLOGOUS CHONDROCYTE IMPLANTATION (ACI)
9.2.1.2 MATRIX-INDUCED AUTOLOGOUS CHONDROCYTE IMPLANTATION (MACI)
9.2.2 STEM CELLS
9.2.2.1 MESENCHYMAL STEM CELLS (MSC'S)
9.2.2.2 UMBILICAL CORD-DERIVED STEM CELL THERAPY
9.2.2.3 EMBRYONIC STEM CELL THERAPY
9.2.2.4 OTHERS
9.2.3 GROWTH FACTOR
9.2.3.1 PLATELET-RICH PLASMA (PRP)
9.2.3.2 AUTOLOGOUS CONDITIONED SERUM (ACS)
9.2.3.3 BONE MORPHOGENETIC PROTEIN (BMP) PRODUCTS
9.2.3.4 FIBROBLAST GROWTH FACTOR (FGF) PRODUCTS
9.2.3.5 CONNECTIVE TISSUE GROWTH FACTOR (CTGF) PRODUCTS
9.2.3.6 OTHERS
9.2.4 OTHERS
9.3 NON - CELL BASED
9.3.1 SCAFFOLDS
9.3.1.1 NATURAL
9.3.1.1.1 HYALURONIC ACID (HA) PRODUCTS
9.3.1.1.2 COLLAGEN-BASED SCAFFOLDS
9.3.1.1.3 CHITOSAN SCAFFOLDS
9.3.1.1.4 DECELLULARIZED EXTRACELLULAR MATRIX
9.3.1.1.5 OTHERS
9.3.1.2 SYNTHETIC
9.3.1.2.1 POLY (LACTIC-CO-GLYCOLIC ACID) (PLGA) SCAFFOLDS
9.3.1.2.2 POLYETHYLENE GLYCOL (PEG) HYDROGELS:
9.3.1.2.3 OTHERS
9.3.2 CELL-FREE COMPOSITES
9.3.2.1 ARTIFICIAL CARTILAGE IMPLANT
9.3.2.2 OTHERS
10 U.S. & EUROPE CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE
10.1 OVERVIEW
10.2 INTRINSIC REPAIR STIMULUS
10.3 PALLIATIVE
10.3.1 DEBRIDEMENT & LAVAGE
10.3.2 VISCOSUPPLEMENTATION
11 U.S. & EUROPE CARTILAGE REGENERATION MARKET, BY APPLICATION SITE
11.1 OVERVIEW
11.2 KNEE
11.2.1 OSTEOCHONDRIAL GRAFTS TRANSPLANTATION
11.2.2 AUTOLOGOUS CHONDROCYTE
11.2.3 ARTHROSCOPIC CHONDROPLASTY
11.2.4 MICROFRACTURE
11.2.5 CELL-BASED CARTILAGE RESURFACING
11.2.6 OTHERS
11.3 HIP
11.4 ANKLE
11.5 SPINE
11.6 OTHERS
12 U.S. & EUROPE CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURES
12.1 OVERVIEW
12.2 OSTEOCHONDRIAL TRANSPLANTATION
12.2.1 OSTEOCHONDRIAL AUTOGRAFT TRANSPLANTATION
12.2.2 OSTEOCHONDRIAL ALLOGRAFT TRANSPLANTATION
12.3 AUTOLOGOUS CHONDROCYTE IMPLANTATION
12.4 MATRIX AUTOLOGOUS CARTILAGE IMPLANTATION (MACI)
12.5 CHONDROPLASTY AND MICROFRACTURE
12.6 OSTEOTOMY
12.7 ARTHROSCOPY
12.8 ABRASION ARTHROPLASTY
12.9 JUVENILE ALLOGRAFT FRAGMENTS
12.1 OTHERS
13 U.S. & EUROPE CARTILAGE REGENERATION MARKET, BY END USER
13.1 OVERVIEW
13.2 HOSPITALS AND CLINICS
13.2.1 PRIVATE
13.2.2 PUBLIC
13.3 ACADEMIC AND RESEARCH INSTITUTES
13.4 AMBULATORY SURGICAL CENTERS
13.5 ORTHOCENTERS
13.6 OTHERS
14 U.S. & EUROPE CARTILAGE REGENERATION MARKET, BY REGION
14.1 U.S.
14.2 EUROPE
14.2.1 GERMANY
14.2.2 U.K.
14.2.3 FRANCE
14.2.4 ITALY
14.2.5 SPAIN
14.2.6 RUSSIA
14.2.7 POLAND
14.2.8 SWITZERLAND
14.2.9 NETHERLANDS
14.2.10 TURKEY
14.2.11 SWEDEN
14.2.12 BELGIUM
14.2.13 DENMARK
14.2.14 FINLAND
14.2.15 NORWAY
14.2.16 REST OF EUROPE
15 U.S. CARTILAGE REGENERATION MARKET: COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: U.S.
15.2 COMPANY SHARE ANALYSIS: EUROPE
16 COMPANY PROFILE
16.1 ZIMMER BIOMET
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 PRODUCT PORTFOLIO
16.1.4 RECENT DEVELOPMENTS
16.2 VERICEL CORPORATION.
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 PRODUCT PORTFOLIO
16.2.4 RECENT DEVELOPMENT
16.3 ARTHREX, INC.
16.3.1 COMPANY SNAPSHOT
16.3.2 PRODUCT PORTFOLIO
16.3.3 RECENT DEVELOPMENT
16.4 CONMED
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 PRODUCT PORTFOLIO
16.4.4 RECENT DEVELOPMENT
16.5 RTI SURGICAL
16.5.1 COMPANY SNAPSHOT
16.5.2 PRODUCT PORTFOLIO
16.5.3 RECENT DEVELOPMENT
16.6 ALLOSOURCE
16.6.1 COMPANY SNAPSHOT
16.6.2 PRODUCT PORTFOLIO
16.6.3 RECENT DEVELOPMENT
16.7 ANIKA THERAPEUTICS, INC.
16.7.1 COMPANY SNAPSHOT
16.7.2 REVENUE ANALYSIS
16.7.3 1.4.4 PRODUCT PORTFOLIO
16.7.4 RECENT DEVELOPMENT
16.8 BIOINOVA, A.S.
16.8.1 COMPANY SNAPSHOT
16.8.2 PRODUCT PORTFOLIO
16.8.3 RECENT DEVELOPMENT
16.9 CARTILAGE INC.
16.9.1 COMPANY SNAPSHOT
16.9.2 PRODUCT PORTFOLIO
16.9.3 RECENT DEVELOPMENT
16.1 CO.DON
16.10.1 COMPANY SNAPSHOT
16.10.2 PRODUCT PORTFOLIO
16.10.3 RECENT DEVELOPMENT
16.11 GEISTLICH PHARMA AG
16.11.1 COMPANY SNAPSHOT
16.11.2 PRODUCT PORTFOLIO
16.11.3 RECENT DEVELOPMENT
16.12 HISTOGEN INC.
16.12.1 COMPANY SNAPSHOT
16.12.2 PRODUCT PORTFOLIO
16.12.3 RECENT DEVELOPMENT
16.13 LAMINA THERAPEUTICS
16.13.1 COMPANY SNAPSHOT
16.13.2 PRODUCT PORTFOLIO
16.13.3 RECENT DEVELOPMENT
16.14 MEIDRIX BIOMEDICALS GMBH
16.14.1 COMPANY SNAPSHOT
16.14.2 PRODUCT PORTFOLIO
16.14.3 RECENT DEVELOPMENT
16.15 NOVARTIS AG
16.15.1 COMPANY SNAPSHOT
16.15.2 PRODUCT PORTFOLIO
16.15.3 RECENT DEVELOPMENT
16.16 SMITH & NEPHEW
16.16.1 COMPANY SNAPSHOT
16.16.2 REVENUE ANALYSIS
16.16.3 PRODUCT PORTFOLIO
16.16.4 RECENT DEVELOPMENTS
16.17 TETEC AG
16.17.1 COMPANY SNAPSHOT
16.17.2 PRODUCT PORTFOLIO
16.17.3 RECENT DEVELOPMENT
17 QUESTIONNAIRE
18 RELATED REPORTS
표 목록
TABLE 1 U.S. NUMBER OF PROCEDURES PER YEAR
TABLE 2 GERMANY NUMBER OF PROCEDURES PER YEAR
TABLE 3 U.K. NUMBER OF PROCEDURES PER YEAR
TABLE 4 FRANCE NUMBER OF PROCEDURES PER YEAR
TABLE 5 ITALY NUMBER OF PROCEDURES PER YEAR
TABLE 6 SPAIN NUMBER OF PROCEDURES PER YEAR
TABLE 7 RUSSIA NUMBER OF PROCEDURES PER YEAR
TABLE 8 POLAND NUMBER OF PROCEDURES PER YEAR
TABLE 9 SWITZERLAND NUMBER OF PROCEDURES PER YEAR
TABLE 10 NETHERLANDS NUMBER OF PROCEDURES PER YEAR
TABLE 11 TURKEY NUMBER OF PROCEDURES PER YEAR
TABLE 12 SWEDEN NUMBER OF PROCEDURES PER YEAR
TABLE 13 BELGIUM NUMBER OF PROCEDURES PER YEAR
TABLE 14 DENMARK NUMBER OF PROCEDURES PER YEAR
TABLE 15 FINLAND NUMBER OF PROCEDURES PER YEAR
TABLE 16 NORWAY NUMBER OF PROCEDURES PER YEAR
TABLE 17 COST OF PROCEDURES
TABLE 18 U.S. & EUROPE CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 19 U.S. & EUROPE FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 20 U.S. & EUROPE CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 21 U.S. & EUROPE CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 22 U.S. & EUROPE CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 23 U.S. & EUROPE STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 24 U.S. & EUROPE GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 25 U.S. & EUROPE NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 26 U.S. & EUROPE SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 27 U.S. & EUROPE SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 28 U.S. & EUROPE SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 29 U.S. & EUROPE CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 30 U.S. & EUROPE CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 31 U.S. & EUROPE PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 32 U.S. & EUROPE CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND)
TABLE 33 U.S. & EUROPE KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 34 U.S. & EUROPE CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND)
TABLE 35 U.S. & EUROPE OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 36 U.S. & EUROPE CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 37 U.S. & EUROPE HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 38 U.S. CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 39 U.S. FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 40 U.S. CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 41 U.S. CELL-BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 42 U.S. CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 43 U.S. STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 44 U.S. GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 45 U.S. NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 46 U.S. SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 47 U.S. NATURAL IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 48 U.S. SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 49 U.S. CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 50 U.S. CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 51 U.S. PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 52 U.S. CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND)
TABLE 53 U.S. KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 54 U.S. CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND)
TABLE 55 U.S. OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 56 U.S. CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 57 U.S. HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 58 EUROPE CARTILAGE REGENERATION MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 59 EUROPE CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 60 EUROPE FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 61 EUROPE CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 62 EUROPE CELL-BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 63 EUROPE CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 64 EUROPE STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 65 EUROPE GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 66 EUROPE NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 67 EUROPE SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 68 EUROPE NATURAL IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 69 EUROPE SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 70 EUROPE CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 71 EUROPE CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 72 EUROPE PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 73 EUROPE CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND)
TABLE 74 EUROPE KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 75 EUROPE CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND)
TABLE 76 EUROPE OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 77 EUROPE CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 78 EUROPE HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 79 GERMANY CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 80 GERMANY FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 81 GERMANY CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 82 GERMANY CELL-BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 83 GERMANY CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 84 GERMANY STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 85 GERMANY GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 86 GERMANY NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 87 GERMANY SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 88 GERMANY NATURAL IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 89 GERMANY SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 90 GERMANY CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 91 GERMANY CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 92 GERMANY PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 93 GERMANY CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND)
TABLE 94 GERMANY KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 95 GERMANY CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND)
TABLE 96 GERMANY OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 97 GERMANY CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 98 GERMANY HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 99 U.K. CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 100 U.K. FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 101 U.K. CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 102 U.K. CELL-BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 103 U.K. CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 104 U.K. STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 105 U.K. GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 106 U.K. NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 107 U.K. SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 108 U.K. NATURAL IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 109 U.K. SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 110 U.K. CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 111 U.K. CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 112 U.K. PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 113 U.K. CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND)
TABLE 114 U.K. KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 115 U.K. CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND)
TABLE 116 U.K. OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 117 U.K. CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 118 U.K. HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 119 FRANCE CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 120 FRANCE FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 121 FRANCE CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 122 FRANCE CELL-BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 123 FRANCE CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 124 FRANCE STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 125 FRANCE GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 126 FRANCE NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 127 FRANCE SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 128 FRANCE NATURAL IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 129 FRANCE SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 130 FRANCE CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 131 FRANCE CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 132 FRANCE PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 133 FRANCE CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND)
TABLE 134 FRANCE KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 135 FRANCE CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND)
TABLE 136 FRANCE OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 137 FRANCE CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 138 FRANCE HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 139 ITALY CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 140 ITALY FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 141 ITALY CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 142 ITALY CELL-BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 143 ITALY CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 144 ITALY STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 145 ITALY GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 146 ITALY NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 147 ITALY SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 148 ITALY NATURAL IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 149 ITALY SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 150 ITALY CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 151 ITALY CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 152 ITALY PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 153 ITALY CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND)
TABLE 154 ITALY KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 155 ITALY CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND)
TABLE 156 ITALY OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 157 ITALY CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 158 ITALY HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 159 SPAIN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 160 SPAIN FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 161 SPAIN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 162 SPAIN CELL-BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 163 SPAIN CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 164 SPAIN STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 165 SPAIN GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 166 SPAIN NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 167 SPAIN SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 168 SPAIN NATURAL IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 169 SPAIN SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 170 SPAIN CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 171 SPAIN CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 172 SPAIN PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 173 SPAIN CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND)
TABLE 174 SPAIN KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 175 SPAIN CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND)
TABLE 176 SPAIN OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 177 SPAIN CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 178 SPAIN HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 179 RUSSIA CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 180 RUSSIA FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 181 RUSSIA CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 182 RUSSIA CELL-BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 183 RUSSIA CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 184 RUSSIA STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 185 RUSSIA GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 186 RUSSIA NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 187 RUSSIA SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 188 RUSSIA NATURAL IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 189 RUSSIA SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 190 RUSSIA CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 191 RUSSIA CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 192 RUSSIA PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 193 RUSSIA CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND)
TABLE 194 RUSSIA KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 195 RUSSIA CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND)
TABLE 196 RUSSIA OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 197 RUSSIA CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 198 RUSSIA HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 199 POLAND CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 200 POLAND FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 201 POLAND CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 202 POLAND CELL-BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 203 POLAND CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 204 POLAND STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 205 POLAND GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 206 POLAND NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 207 POLAND SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 208 POLAND NATURAL IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 209 POLAND SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 210 POLAND CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 211 POLAND CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 212 POLAND PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 213 POLAND CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND)
TABLE 214 POLAND KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 215 POLAND CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND)
TABLE 216 POLAND OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 217 POLAND CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 218 POLAND HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 219 SWITZERLAND CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 220 SWITZERLAND FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 221 SWITZERLAND CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 222 SWITZERLAND CELL-BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 223 SWITZERLAND CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 224 SWITZERLAND STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 225 SWITZERLAND GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 226 SWITZERLAND NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 227 SWITZERLAND SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 228 SWITZERLAND NATURAL IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 229 SWITZERLAND SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 230 SWITZERLAND CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 231 SWITZERLAND CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 232 SWITZERLAND PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 233 SWITZERLAND CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND)
TABLE 234 SWITZERLAND KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 235 SWITZERLAND CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND)
TABLE 236 SWITZERLAND OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 237 SWITZERLAND CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 238 SWITZERLAND HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 239 NETHERLANDS CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 240 NETHERLANDS FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 241 NETHERLANDS CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 242 NETHERLANDS CELL-BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 243 NETHERLANDS CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 244 NETHERLANDS STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 245 NETHERLANDS GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 246 NETHERLANDS NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 247 NETHERLANDS SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 248 NETHERLANDS NATURAL IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 249 NETHERLANDS SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 250 NETHERLANDS CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 251 NETHERLANDS CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 252 NETHERLANDS PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 253 NETHERLANDS CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND)
TABLE 254 NETHERLANDS KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 255 NETHERLANDS CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND)
TABLE 256 NETHERLANDS OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 257 NETHERLANDS CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 258 NETHERLANDS HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 259 TURKEY CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 260 TURKEY FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 261 TURKEY CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 262 TURKEY CELL-BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 263 TURKEY CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 264 TURKEY STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 265 TURKEY GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 266 TURKEY NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 267 TURKEY SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 268 TURKEY NATURAL IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 269 TURKEY SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 270 TURKEY CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 271 TURKEY CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 272 TURKEY PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 273 TURKEY CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND)
TABLE 274 TURKEY KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 275 TURKEY CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND)
TABLE 276 TURKEY OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 277 TURKEY CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 278 TURKEY HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 279 SWEDEN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 280 SWEDEN FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 281 SWEDEN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 282 SWEDEN CELL-BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 283 SWEDEN CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 284 SWEDEN STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 285 SWEDEN GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 286 SWEDEN NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 287 SWEDEN SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 288 SWEDEN NATURAL IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 289 SWEDEN SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 290 SWEDEN CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 291 SWEDEN CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 292 SWEDEN PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 293 SWEDEN CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND)
TABLE 294 SWEDEN KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 295 SWEDEN CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND)
TABLE 296 SWEDEN OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 297 SWEDEN CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 298 SWEDEN HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 299 BELGIUM CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 300 BELGIUM FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 301 BELGIUM CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 302 BELGIUM CELL-BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 303 BELGIUM CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 304 BELGIUM STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 305 BELGIUM GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 306 BELGIUM NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 307 BELGIUM SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 308 BELGIUM NATURAL IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 309 BELGIUM SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 310 BELGIUM CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 311 BELGIUM CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 312 BELGIUM PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 313 BELGIUM CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND)
TABLE 314 BELGIUM KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 315 BELGIUM CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND)
TABLE 316 BELGIUM OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 317 BELGIUM CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 318 BELGIUM HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 319 DENMARK CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 320 DENMARK FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 321 DENMARK CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 322 DENMARK CELL-BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 323 DENMARK CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 324 DENMARK STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 325 DENMARK GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 326 DENMARK NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 327 DENMARK SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 328 DENMARK NATURAL IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 329 DENMARK SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 330 DENMARK CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 331 DENMARK CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 332 DENMARK PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 333 DENMARK CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND)
TABLE 334 DENMARK KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 335 DENMARK CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND)
TABLE 336 DENMARK OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 337 DENMARK CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 338 DENMARK HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 339 FINLAND CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 340 FINLAND FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 341 FINLAND CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 342 FINLAND CELL-BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 343 FINLAND CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 344 FINLAND STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 345 FINLAND GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 346 FINLAND NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 347 FINLAND SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 348 FINLAND NATURAL IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 349 FINLAND SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 350 FINLAND CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 351 FINLAND CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 352 FINLAND PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 353 FINLAND CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND)
TABLE 354 FINLAND KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 355 FINLAND CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND)
TABLE 356 FINLAND OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 357 FINLAND CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 358 FINLAND HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 359 NORWAY CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 360 NORWAY FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 361 NORWAY CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 362 NORWAY CELL-BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 363 NORWAY CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 364 NORWAY STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 365 NORWAY GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 366 NORWAY NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 367 NORWAY SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 368 NORWAY NATURAL IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 369 NORWAY SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 370 NORWAY CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 371 NORWAY CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 372 NORWAY PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 373 NORWAY CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND)
TABLE 374 NORWAY KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 375 NORWAY CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND)
TABLE 376 NORWAY OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 377 NORWAY CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 378 NORWAY HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 379 REST OF EUROPE CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
그림 목록
FIGURE 1 U.S. & EU CARTILAGE REGENERATION MARKET: SEGMENTATION
FIGURE 2 U.S. & EU CARTILAGE REGENERATION MARKET: DATA TRIANGULATION
FIGURE 3 U.S. & EU CARTILAGE REGENERATION MARKET: DROC ANALYSIS
FIGURE 4 U.S. & EU CARTILAGE REGENERATION MARKET: REGIONAL VS COUNTRYMARKET ANALYSIS
FIGURE 5 U.S. & EU CARTILAGE REGENERATION MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 U.S. & EU CARTILAGE REGENERATION MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 U.S. & EU CARTILAGE REGENERATION MARKET: MARKET END USER COVERAGE GRID
FIGURE 8 U.S. & EU CARTILAGE REGENERATION MARKET: DBMR MARKET POSITION GRID
FIGURE 9 U.S. & EU CARTILAGE REGENERATION MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 U.S. & EU CARTILAGE REGENERATION MARKET: SEGMENTATION
FIGURE 11 RISING PREVALENCE OF OSTEOARTHRITIS AND RISING HEALTHCARE EXPENDITURE ARE DRIVING THE GROWTH OF THE U.S. & EU CARTILAGE REGENERATION MARKET FROM 2024 TO 2034
FIGURE 12 HYALINE CARTILAGE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE U.S. AND EU CARTILAGE REGENERATION MARKET IN 2024 TO 2031
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE U.S. & EU CARTILAGE REGENERATION MARKET
FIGURE 14 U.S. & EUROPE CARTILAGE REGENERATION MARKET : BY TYPE, 2023
FIGURE 15 U.S. & EUROPE CARTILAGE REGENERATION MARKET : BY TYPE, 2024-2031 (USD THOUSAND)
FIGURE 16 U.S. & EUROPE CARTILAGE REGENERATION MARKET : BY TYPE, CAGR (2024-2031)
FIGURE 17 U.S. & EUROPE CARTILAGE REGENERATION MARKET : BY TYPE, LIFELINE CURVE
FIGURE 18 U.S. & EUROPE CARTILAGE REGENERATION MARKET: BY TREATMENT MODALITY, 2022
FIGURE 19 U.S. & EUROPE CARTILAGE REGENERATION MARKET: BY TREATMENT MODALITY, 2024-2031 (USD THOUSAND)
FIGURE 20 U.S. & EUROPE CARTILAGE REGENERATION MARKET: BY TREATMENT MODALITY, CAGR (2024-2031)
FIGURE 21 U.S. & EUROPE CARTILAGE REGENERATION MARKET: BY TREATMENT MODALITY, LIFELINE CURVE
FIGURE 22 U.S. & EUROPE CARTILAGE REGENERATION MARKET: BY TREATMENT TYPE, 2022
FIGURE 23 U.S. & EUROPE CARTILAGE REGENERATION MARKET: BY TREATMENT TYPE, 2024-2031 (USD THOUSAND)
FIGURE 24 U.S. & EUROPE CARTILAGE REGENERATION MARKET: BY TREATMENT TYPE, CAGR (2024-2031)
FIGURE 25 U.S. & EUROPE CARTILAGE REGENERATION MARKET: BY TREATMENT TYPE, LIFELINE CURVE
FIGURE 26 U.S. & EUROPE CARTILAGE REGENERATION MARKET : BY APPLICATION SITE, 2023
FIGURE 27 U.S. & EUROPE CARTILAGE REGENERATION MARKET : BY APPLICATION SITE, 2024-2031 (USD THOUSAND)
FIGURE 28 U.S. & EUROPE CARTILAGE REGENERATION MARKET : BY APPLICATION SITE, CAGR (2024-2031)
FIGURE 29 U.S. & EUROPE CARTILAGE REGENERATION MARKET : BY APPLICATION SITE, LIFELINE CURVE
FIGURE 30 U.S. & EUROPE CARTILAGE REGENERATION MARKET : BY SURGICAL PROCEDURE , 2023
FIGURE 31 U.S. & EUROPE CARTILAGE REGENERATION MARKET : BY SURGICAL PROCEDURE , 2024-2031 (USD THOUSAND)
FIGURE 32 U.S. & EUROPE CARTILAGE REGENERATION MARKET : BY SURGICAL PROCEDURE, CAGR (2024-2031)
FIGURE 33 U.S. & EUROPE CARTILAGE REGENERATION MARKET : BY SURGICAL PROCEDURE, LIFELINE CURVE
FIGURE 34 U.S. & EUROPE CARTILAGE REGENERATION MARKET : BY END USER, 2023
FIGURE 35 U.S. & EUROPE CARTILAGE REGENERATION MARKET : BY END USER, 2024-2031 (USD THOUSAND)
FIGURE 36 U.S. & EUROPE CARTILAGE REGENERATION MARKET : BY END USER, CAGR (2024-2031)
FIGURE 37 U.S. & EUROPE CARTILAGE REGENERATION MARKET : BY END USER, LIFELINE CURVE
FIGURE 38 EUROPE CARTILAGE REGENERATION MARKET: SNAPSHOT (2023)
FIGURE 39 U.S. CARTILAGE REGENERATION MARKET: COMPANY SHARE 2023 (%)
FIGURE 40 EUROPE CARTILAGE REGENERATION MARKET: COMPANY SHARE 2023 (%)
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.
